Opus Genetics, Inc. (IRD)
| Market Cap | 476.71M +495.4% |
| Revenue (ttm) | 9.86M -36.1% |
| Net Income | -107.61M |
| EPS | -1.29 |
| Shares Out | 83.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 54,319,720 |
| Open | 5.31 |
| Previous Close | 4.34 |
| Day's Range | 5.31 - 7.07 |
| 52-Week Range | 1.32 - 7.07 |
| Beta | 0.58 |
| Analysts | Strong Buy |
| Price Target | 10.71 (+86.91%) |
| Earnings Date | Aug 6, 2026 |
About IRD
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets ... [Read more]
Financial Performance
In 2025, Opus Genetics's revenue was $14.20 million, an increase of 29.15% compared to the previous year's $10.99 million. Losses were -$49.59 million, -13.80% less than in 2024.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for IRD stock is "Strong Buy." The 12-month stock price target is $10.71, which is an increase of 86.91% from the latest price.
News
Opus Genetics price target raised to $14 from $11 at Leerink
Leerink raised the firm’s price target on Opus Genetics (IRD) to $14 from $11 and keeps an Outperform rating on the shares. The company’s low-dose Cohort 1 of BIRD-1, its…
Opus Genetics price target raised to $20 from $10 at Oppenheimer
Oppenheimer raised the firm’s price target on Opus Genetics (IRD) to $20 from $10 and keeps an Outperform rating on the shares after the company reported results from the low-dose…
Opus Genetics price target raised to $16 from $13 at Chardan
Chardan analyst Andreas Argyrides raised the firm’s price target on Opus Genetics (IRD) to $16 from $13 and keeps a Buy rating on the shares following positive low-dose proof-of-concept data…
Opus Genetics Transcript: Study result
The phase I/II trial of OPGX-BEST1 gene therapy in BVMD and ARB showed strong safety and promising efficacy, with all participants experiencing functional gains and most showing structural improvements. FDA alignment on a composite microperimetry and PRO endpoint paves the way for phase III, which will focus on earlier-stage patients and refined targeting.
Opus Genetics Slides: Study result
Opus Genetics has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Opus Genetics Press release: Study result
Opus Genetics issued a press release on September 9, 2026, disclosing material business information to investors.
Opus Genetics announces results from low-dose Cohort 1 of BIRD-1 trial
Opus Genetics (IRD) announced 3- and 6-month results from the low-dose Cohort 1 of BIRD-1, its ongoing Phase 1/2 clinical trial evaluating OPGx-BEST1 in patients with BEST1-related retinal diseases, i...
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improv...
Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ET Full clinical dataset and additional ...
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent bl...
Opus Genetics price target lowered to $9 from $10 at RBC Capital
RBC Capital lowered the firm’s price target on Opus Genetics (IRD) to $9 from $10 and keeps an Outperform rating on the shares.
Opus Genetics Registration statement: Registration filing
Opus Genetics filed a registration statement on August 7, 2026, providing details about a securities offering with the SEC.
Opus Genetics files $300M mixed securities shelf
06:23 EDT Opus Genetics (IRD) files $300M mixed securities shelf
Opus Genetics reports Q2 EPS (14c), consensus (16c)
Reports Q2 revenue $755,000, consensus $2.57M. “With a focus on execution, we are rapidly advancing five gene therapy programs that address significant unmet need in inherited retinal diseases, with O...
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
Opus Genetics Earnings release: Q2 2026
Opus Genetics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Opus Genetics Quarterly report: Q2 2026
Opus Genetics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Opus Genetics enrolls last patient in OPGx-LCA5 trial
Opus Genetics (IRD) announced that the last patient has been enrolled in its registrational Phase 3 clinical trial evaluating OPGx-LCA5, the company’s investigational gene therapy for LCA5-associated ...
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
Topline six-month efficacy data expected by end of 2027 Phase 3 study follows FDA alignment on registrational trial design through Rare Disease Evidence Principles (RDEP) program Opus Genetics may sub...
Opus Genetics initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Opus Genetics (IRD) with a Buy rating without a price target The company’s adeno-associated virus gene therapies replenish wild-type copies of pathological genes that dr...
Opus Genetics sets September timeline for retinal disease trial data
Opus Genetics (IRD) provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial targeting BEST-1 associated inherited retinal diseases. The company expects to announce three-month topline data...
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene...
Opus Genetics FDA alignment further de-risks path to market, says Chardan
After Opus Genetics (IRD) announced that it has reached alignment with the FDA on the design of its registrational Phase 3 clinical trial evaluating OPGx-LCA5 for LCA5-associated IRD, an early-onset…
Opus Genetics announces FDA alignment on OPGx-LCA5 trial
Opus Genetics (IRD) announced that it has reached alignment with the FDA in a Type B Rare Disease Evidence Principles, or RDEP, meeting on the design of its registrational Phase…
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
Successful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study design FDA indicates Opus Genetics may submit a BLA based on 6-month efficacy data, with 12-month durability data provide...